Category Patents/Designs/Trade Secrets

WIPO Seminar Discusses Impact Of TRIPS On Pharmaceutical Innovation

The latest instalment of the World Intellectual Property Organization seminar series titled “The Economics of Intellectual Property” covered the issue of product patents in the pharmaceutical industry. Discussion focussed on the economics of intellectual property rights and how pharmaceutical patent protection might not be the sole culprit in the access to innovation problem.

US Supreme Court Rules On Pharma Payments To Delay Generic Drugs On Market

The United States Supreme Court in a five to three decision today found that settlement agreements by branded pharmaceutical companies involving payments to generic companies to delay their cheaper drugs' entry into the market may not be immune from antitrust scrutiny but are not "presumptively" unlawful. The case was sent back to lower court.

US Supreme Court Restricts Gene Patents … A Little

Last Thursday, the United States Supreme Court overturned more than 30 years of precedents and ruled that isolated genes cannot be patented. They are products of nature and thus not patent-eligible subject matter, the court unanimously held in Assoc. for Molecular Pathology v. Myriad Genetics, Inc. This ruling puts the US at odds with most other nations, which allow genes to be patented. But because other major nations grant narrower gene patents, the net effect of Myriad will be to shift the US position on gene patents closer to that of other nations.